|4Jul 26, 5:02 PM ET

Henig Noreen 4

4 · Kezar Life Sciences, Inc. · Filed Jul 26, 2023

Insider Transaction Report

Form 4
Period: 2023-07-24
Henig Noreen
Chief Medical Officer
Transactions
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2023-07-24280,0000 total
    Exercise: $5.45Exp: 2031-01-07Common Stock (280,000 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2023-07-24180,0000 total
    Exercise: $14.55Exp: 2032-01-04Common Stock (180,000 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2023-07-24220,0000 total
    Exercise: $6.84Exp: 2033-01-07Common Stock (220,000 underlying)
  • Disposition to Issuer

    Employee Stock Option (right to buy)

    2023-07-24300,0000 total
    Exercise: $4.56Exp: 2030-04-30Common Stock (300,000 underlying)
  • Award

    Employee Stock Option (right to buy)

    2023-07-24+300,000300,000 total
    Exercise: $2.28Exp: 2030-04-30Common Stock (300,000 underlying)
  • Award

    Employee Stock Option (right to buy)

    2023-07-24+280,000280,000 total
    Exercise: $2.28Exp: 2031-01-07Common Stock (280,000 underlying)
  • Award

    Employee Stock Option (right to buy)

    2023-07-24+180,000180,000 total
    Exercise: $2.28Exp: 2032-01-04Common Stock (180,000 underlying)
  • Award

    Employee Stock Option (right to buy)

    2023-07-24+220,000220,000 total
    Exercise: $2.28Exp: 2033-01-07Common Stock (220,000 underlying)
Footnotes (5)
  • [F1]Twenty-five percent (25%) of the shares subject to the option vested on May 1, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such vesting date.
  • [F2]On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged.
  • [F3]One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 1, 2021, subject to the Reporting Person continuing to provide service through each such date.
  • [F4]One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 5, 2022, subject to the Reporting Person continuing to provide service through each such date.
  • [F5]One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 8, 2023, subject to the Reporting Person continuing to provide service through each such date.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION